Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
Open accessThe DOI matches its Crossref record; 134 of the 141 references it cites were found in a registry or an index; 90 of the 190 sources its claims cite were checked for support.
Abstract
OBJECTIVE: To review the evidence about the impact of hypoglycemia on patients with diabetes that has become available since the past reviews of this subject by the American Diabetes Association and The Endocrine Society and to provide guidance about how this new information should be incorporated into clinical practice. PARTICIPANTS: Five members of the American Diabetes Association and five members of The Endocrine Society with expertise in different aspects of hypoglycemia were invited by the Chair, who is a member of both, to participate in a planning conference call and a 2-day meeting that was also attended by staff from both organizations. Subsequent communications took place via e-mail and phone calls. The writing group consisted of those invitees who participated in the writing of the manuscript. The workgroup meeting was supported by educational grants to the American Diabetes Association from Lilly USA, LLC and Novo Nordisk and sponsorship to the American Diabetes Association from Sanofi. The sponsors had no input into the development of or content of the report. EVIDENCE: The writing group considered data from recent clinical trials and other studies to update the prior workgroup report. Unpublished data were not used. Expert opinion was used to develop some conclusions. CONSENSUS PROCESS: Consensus was achieved by group discussion during conference calls and face-to-face meetings, as well as by iterative revisions of the written document. The document was reviewed and approved by the American Diabetes Association's Professional Practice Committee in October 2012 and approved by the Executive Committee of the Board of Directors in November 2012 and was reviewed and approved by The Endocrine Society's Clinical Affairs Core Committee in October 2012 and by Council in November 2012. CONCLUSIONS: The workgroup reconfirmed the previous definitions of hypoglycemia in diabetes, reviewed the implications of hypoglycemia on both short- and long-term outcomes, considered the implications of hypoglycemia on treatment outcomes, presented strategies to prevent hypoglycemia, and identified knowledge gaps that should be addressed by future research. In addition, tools for patients to report hypoglycemia at each visit and for clinicians to document counseling are provided.
Overview
CoChat Summary
TL;DR
This ADA/Endocrine Society workgroup report updates definitions, risks, and prevention strategies for hypoglycemia in diabetes, with a strong emphasis on avoiding severe episodes and hypoglycemia unawareness. It argues for individualized glycemic targets, better monitoring and education, and further research on outcomes, measurement, and new therapies.
Key findings
- The workgroup defines iatrogenic hypoglycemia as all episodes of abnormally low plasma glucose that expose the person to potential harm, and recommends an alert value of ≤70 mg/dL (≤3.9 mmol/L) for patients at risk; it also classifies episodes as severe, documented symptomatic, asymptomatic, probable symptomatic, or pseudo-hypoglycemia.
- Severe hypoglycemia rates reported in the paper ranged from 115 to 320 per 100 patient-years in type 1 diabetes and 35 to 70 per 100 patient-years in type 2 diabetes; because type 2 diabetes is more common, most hypoglycemia episodes occur in people with type 2 diabetes.
- In ACCORD, intensive glycemic control produced threefold higher hypoglycemia and a 20% increase in mortality; post hoc analyses in ACCORD found severe hypoglycemia had a hazard ratio of 1.41 (95% CI 1.03–1.93) for death.
- In hospitalized patients, one retrospective study found 10.5% of 31,970 general-ward admissions had at least one hypoglycemic episode (≤70 mg/dL), and severe hypoglycemia (≤50 mg/dL) was associated with increased length of stay and greater odds of inpatient death and death within 1 year of discharge.
Methods
- This is a workgroup report/consensus document, not an experimental study; five ADA and five Endocrine Society experts were invited, held a planning call and a 2-day meeting, and developed the manuscript through discussion and iterative revisions.
- The group reviewed recent clinical trials and other studies published since the prior reports; unpublished data were not used, and some conclusions relied on expert opinion.
- Consensus was reached by group discussion and was reviewed/approved by both organizations’ committees in October and November 2012.
Limitations
- The paper states that unpublished data were not used, and that expert opinion was used to develop some conclusions.
- The text makes evident that some evidence is observational, post hoc, or limited by small studies, so causal inference is uncertain in several areas (e.g., mortality, cognition); this is an inference from the paper’s cited evidence, not a limitation explicitly stated in one place.
- The paper explicitly notes gaps in knowledge on hypoglycemia outcomes, mechanisms, and prevention, indicating that several recommendations are based on incomplete evidence.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Valid · 5 Not valid · 33 Not checked · 7 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“There is convincing evidence that formal training programs that teach patients to replace insulin “physiologically” by giving background and mealtime/correction doses of insulin can reduce the risk of severe hypoglycemia.”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > What strategies are known to prevent hypoglycemia, and what are the clinical recommendations for those at risk for hypoglycemia? > Patient education
What the sources say
- Supportedcites [100] Mühlhauser, 2002, Patient education—evaluation of a complex intervention, Diabetologia source
The Modelling section describes a structured programme teaching patients to adjust insulin doses, using NPH insulin twice daily and regular insulin before meals. The Long-term implementation section reports decreased rates of severe hypoglycaemia in patients with Type I diabetes and says several prospective studies observed that reduction. The paper supports that such programmes can reduce the risk, although not every evaluation found a reduction. (LLM, conf=0.90)
- Partly supportedcites [101] Bott, 1997, Intensified insulin therapy and the risk of severe hypoglycaemia, Diabetologia sourceExperimental — accuracy not yet measured
The Subjects and methods passage describes structured training in background and mealtime insulin dosing, with patients adjusting doses for glucose and carbohydrate intake. The Results and Discussion report fewer severe hypoglycaemic episodes after the programme, but describe the reduction as an association; they do not establish that training itself caused it. The claim’s description of this as convincing evidence that the programmes can reduce risk is therefore stronger than the paper’s finding. (LLM, conf=0.84)
- Supportedcites [102] Sämann, 2005, Glycaemic control and severe hypoglycaemia following training in flexible, intensive insulin therapy to enable dietary freedom in people with type 1 diabetes: a prospective implementation study, Diabetologia source
The Subjects and methods section describes a structured course teaching background insulin injections and meal-by-meal dose adjustments based on blood glucose and carbohydrate intake. The Abstract reports that severe hypoglycaemia fell from 0.37 to 0.14 events per patient per year after training among people with type 1 diabetes. (LLM, conf=0.92)
- Disputedcites [103] DAFNE Study Group, 2002, Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial, BMJ sourceExperimental — accuracy not yet measured
The skills course section describes training patients to adjust insulin to their meals. But the paper reports that severe hypoglycaemia remained unchanged; the Discussion says there was no significant increase, not a reduction in risk. The claimed risk reduction is therefore contrary to the reported finding. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [104] McIntyre, 2010, Dose adjustment for normal eating (DAFNE)—an audit of outcomes in Australia, Med J Aust source
- Partly supportedcites [105] Hopkins, 2012, Improved biomedical and psychological outcomes 1 year after structured education in flexible insulin therapy for people with type 1 diabetes: the U.K. DAFNE experience, Diabetes Care sourceExperimental — accuracy not yet measured
The Results and Conclusions (pages not provided) report fewer severe hypoglycemia episodes after DAFNE, a structured education program for adults with type 1 diabetes. The paper describes adjusting insulin to carbohydrate intake, but does not specify the claimed background and mealtime/correction-dose teaching. Its evidence is also a retrospective audit based on self-reported hypoglycemia, which qualifies the claim of ‘convincing evidence.’ (LLM, conf=0.82)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12)”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion states that after an episode of hypoglycemia, the authors found elevated glycemic thresholds for neurogenic and neuroglycopenic symptoms, including in patients with IDDM in the present study. Its terminology indicates that an elevated threshold means symptoms occur at a lower plasma glucose concentration. The Results also report reduced symptom responses after antecedent hypoglycemia. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In critical care units, where the accuracy of POC meters is particularly crucial, their performance may be compromised by medications (vasopressors, acetaminophen), treatments (oxygen), and clinical states (hypotension, anemia) (17).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported? > The challenge of measuring glucose accurately
What the sources say
- Partly supportedcites [17] Klonoff, 2011, Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline, J Clin Endocrinol Metab sourceExperimental — accuracy not yet measured
Section 1.1 Evidence says supplemental oxygen can cause falsely low readings with glucose-oxidase meters and identifies acetaminophen, pressor use, and hypotension as potential concerns for POC testing in critically ill patients. It also reports an accuracy discrepancy among patients with hypotension or pressor treatment. The cited passages do not address anemia as a cause of compromised meter performance. (LLM, conf=0.88)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A single threshold value for plasma glucose concentration that defines hypoglycemia in diabetes cannot be assigned because glycemic thresholds for symptoms of hypoglycemia (among other responses) shift to lower plasma glucose concentrations after recent antecedent hypoglycemia (9–12) and to higher plasma glucose concentrations in patients with poorly controlled diabetes and infrequent hypoglycemia”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Not checked — no full text of the sourcecites [9] Amiel, 1988, Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release, Diabetes source
- Supportedcites [10] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia, J Clin Invest source
The Discussion (p. 823) reports that antecedent hypoglycemia changes the glycemic threshold for symptoms in patients with insulin-dependent diabetes. The Discussion also reports symptoms at higher plasma glucose concentrations in patients with poorly or moderately controlled diabetes. Together, these findings support the claim that no single symptom-based plasma glucose threshold applies across these circumstances. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [11] Davis, 1997, Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans, Diabetes source
- Not checked — no full text of the sourcecites [12] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans, Diabetes source
- Not checked — no full text of the sourcecites [13] Boyle, 1988, Plasma glucose concentrations at the onset of hypoglycemic symptoms in patients with poorly controlled diabetes and in nondiabetics, N Engl J Med source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Hypoglycemia puts patients at risk for injury and death.”
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
“There is no doubt that hypoglycemia can be fatal (26).”
§ Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society > How should hypoglycemia in diabetes be defined and reported?
What the sources say
- Supportedcites [26] Cryer, 2011, Death during intensive glycemic therapy of diabetes: mechanisms and implications, Am J Med source
In the main text (page unavailable), Cryer states that iatrogenic hypoglycemia causes recurrent morbidity in people with diabetes and is sometimes fatal. This supports the broad claim that hypoglycemia puts these patients at risk of harm and death. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § What are the implications of hypoglycemia on both short- and long-term outcomes in people with diabetes? · plain
76 more claims · 43 with their cited sources checked
Create a free account to see all 104 claims and to verify the 4 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Postprandial hyperglycemia and resultant compensatory hyperinsulinemia from high dietary glycemic load can lower plasma glucose to concentrations that compromise brain glucose, w70 mg/dL (3.8 mmol/L) (36), triggering the secretion of autonomic counterregulatory hormones such as adrenaline, cortisol, glucagon, and growth hormone (37).”
From High glycemic index diet as a risk factor for depression: analyses from the Women’s Health Initiative (2015) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risks for hypoglycemia, particularly level 3 hypoglycemia, include longer duration of diabetes, older age, history of recent level 3 hypoglycemia, alcohol ingestion, exercise, lower education levels, lower household incomes (41), chronic kidney disease, and IAH (103-105).”
From The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (2021) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recurrent hypoglycaemia results in an increased likelihood of hypoglycaemia unawareness and subsequent severe hypoglycaemic events, since recurrent hypoglycaemia reduces the glucose concentration that triggers the counter-regulatory responses to return to euglycaemia.106”
From Type 1 diabetes (2018) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“Hypoglycemia is a frequent and dangerous complication of diabetes (1), causing changes in physiological parameters (2,3).”
From Noninvasive Hypoglycemia Detection in People With Diabetes Using Smartwatch Data (2023) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“Individualized glucose targets, patient education, nutrition intervention (e.g., bedtime snack to prevent overnight hypoglycemia when specifically needed to treat low blood glucose), physical activity management, medication adjustment, glucose monitoring, and routine clinical surveillance may improve patient outcomes (94).”
From 6. Glycemic Targets: Standards of Care in Diabetes—2023 (2023) · cites this paper as [94]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Self-check results appear here once an independent check has confirmed them.
Cited works that were retracted
Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.
A note, not an issue: for example, a cited work that was retracted only after this paper was published, which its authors could not have known.
In the paper
“Deakin T McShane CE Cade JE Williams RD Group based training for self-management strategies in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; 2: CD003417 15846663”
Cited work 10.1002/14651858.cd003417.pub2 · retracted 2015-06-30 · notice 10.1002/14651858.cd003417.pub3 · this paper published 2013-04-13
Citations
Cites
1 retracted
Group based training for self-management strategies in people with type 2 diabetes mellitus
Deakin, T. A., McShane, C. E., Cade, J. E., & Williams, R. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003417.pub2 · Cited by 862
RetractedIntensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Hyperglycemia and adverse pregnancy outcomes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707943 · Cited by 5,563
Intensive versus Conventional Glucose Control in Critically Ill Patients
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810625 · Cited by 5,119
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762 · cited 1×
“In VADT, a recent severe hypoglycemic event was the strongest independent predictor of death at 90 days (3).”
BackgroundInzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919 · cited 2×
“event of troublesome hypoglycemia (96).”
BackgroundIntensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
Research works printed but not linked: 2
- Reno, 2011, Deaths due to severe hypoglycemia are exacerbated by diabetes and ameliorated by hypoglycemic pre-conditioning (Abstract), Diabetes, 60, A81
- Aubert, 1995, Diabetes-Related Hospitalization and Hospital Utilization
Cited by
Items 301–400 of 1,392
de Galan, B. E., McCrimmon, R. J., Ibberson, M. R., Heller, S. R., Choudhary, P., Pouwer, F., Speight, J., Carlton, J., Pieber, T. R., Rosilio, M., et al. (2020) · Diabetic Medicine · doi:10.1111/dme.14240 · Cited by 44
Self-citationConsiderations and challenges of islet transplantation and future therapies on the horizon
Walker, S. L. M., Appari, M., & Forbes, S. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00310.2021 · Cited by 51
Han, E., Han, K.-D., Lee, B.-W., Kang, E. S., Cha, B.-S., Ko, S.-H., & Lee, Y.-H. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab860 · Cited by 41
“We previously defined severe hypoglycemia as any hypoglycemic event requiring the assistance of another person to actively administer carbohydrates, or the need for corrective action, hospitalization, or adjustment of medical treatment (9, 17).”
BackgroundZhang, L., Yang, L., & Zhou, Z. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1044059 · Cited by 46
Yonamine, C. Y., Michalani, M. L. E., Moreira, R. J., & Machado, U. F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216480 · Cited by 54
“…the relationship between DM and cognitive impairment, we must first point out that although DM is defined as a hyperglycemic disease, iatrogenic recurrent hypoglycemia will occur to a greater or lesser degree in consequence of sulfonylurea, glinide, or insulin treatments (for a review, see [82,83]).”
BackgroundPancreas transplantation: a treatment option for people with diabetes
Mittal, S., & Gough, S. C. L. (2014) · Diabetic Medicine · doi:10.1111/dme.12373 · Cited by 50
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Yun, J., & Ko, S. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.1.6 · Cited by 43
“Generally, a plasma glucose concentration ≤ 70 mg/dL is the cut-off value for the definition of hypoglycemia [10].”
BackgroundInfluentialPhilis‐Tsimikas, A., Astamirova, K., Gupta, Y., Haggag, A. Z., Roula, D., Bak, B. A., Fita, E. G., Nielsen, A. M., & Demir, T. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.10.024 · Cited by 42
Management of diabetes mellitus in chronic kidney disease
Garla, V. V., Kanduri, S. R., Yanes-Cardozo, L. L., & Lien, L. F. (2019) · Minerva Endocrinology · doi:10.23736/s0391-1977.19.03015-3 · Cited by 46
Phillip, M., Mathieu, C., Lind, M., Araki, E., di Bartolo, P., Bergenstal, R., Heller, S., Hansen, L., Scheerer, M. F., Thoren, F., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14248 · Cited by 41
“Hypoglycaemic events were defined according to the American Diabetes Association (ADA) classification criteria.(9,10) Severe hypoglycaemia was defined as an event resulting in unconsciousness caused by hypoglycaemia or an event requiring the assistance of another person to administer carbohydrate, glucagon, or to take…”
BackgroundMethodSelf-citationSchernthaner, G., Barnett, A. H., Patel, S., Hehnke, U., von Eynatten, M., & Woerle, H. J. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12321 · Cited by 41
“All rights reserved responses, and reduced awareness of hypoglycaemic symptoms [36].”
BackgroundMcEwan, P., Thorsted, B. L., Wolden, M. L., Jacobsen, J., & Evans, M. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2014-000057 · Cited by 46
Blood glucose level prediction based on support vector regression using mobile platforms
Reymann, M. P., Dorschky, E., Groh, B. H., Martindale, C., Blank, P., & Eskofier, B. M. (2016) · 2016 38th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC) · doi:10.1109/embc.2016.7591358 · Cited by 40
“dL [5].”
Qi, X., Xu, J., Chen, G., Liu, H., Liu, J., Wang, J., Zhang, X., Hao, Y., Wu, Q., & Jiao, M. (2021) · Health and Quality of Life Outcomes · doi:10.1186/s12955-021-01881-y · Cited by 48
Liu, L., Shi, H., Shi, Y., Wang, A., Guo, N., Tao, H., & Nahata, M. C. (2024) · Pharmaceuticals · doi:10.3390/ph17070828 · Cited by 40
“Safety outcomes were frequently reported adverse events, including the proportion of patients with nausea, vomiting, diarrhea, abdominal pain, headache, injection-site reaction, and hypoglycemia as defined by the American Diabetes Association [57].”
BackgroundArnold, P. C., Scheurer, D. B., Dake, A. W., Hedgpeth, A., Hutto, A. C., Colquitt, C., & Hermayer, K. L. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2015.11.024 · Cited by 42
Zhuang, X., He, X., Yang, D.-Y. D., Guo, Y., He, J., Xiao, H., & Liao, X. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0722-z · Cited by 43
Hypoglycemia and Incident Cognitive Dysfunction: A Post Hoc Analysis From the ORIGIN Trial
Cukierman-Yaffe, T., Bosch, J., Jung, H., Punthakee, Z., & Gerstein, H. C. (2019) · Diabetes Care · doi:10.2337/dc18-0690 · Cited by 39
“The same analyses were repeated after replacing severe hypoglycemia with nonsevere hypoglycemia, after accounting for the competing risk of death (10), after adjusting for age at the time that data were censored for each participant, and after additionally adjusting for A1C as a timevarying covariate.”
BackgroundNørgaard, S. K., Mathiesen, E. R., Nørgaard, K., & Ringholm, L. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0109 · Cited by 38
Nikolic, D., Patti, A. M., Giglio, R. V., Chianetta, R., Castellino, G., Magán-Fernández, A., Citarrella, R., Papanas, N., Janez, A., Stoian, A. P., et al. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01217-z · Cited by 38
“Diabetes Association and the Endocrine Society) [18] were recorded.”
BackgroundThe management of severe hypoglycemia by the emergency system: The HYPOTHESIS study
Marchesini, G., Veronese, G., Forlani, G., Forlani, G., Ricciardi, L. M., & Fabbri, A. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.012 · Cited by 42
Edelman, S. V., & Blose, J. S. (2014) · The Science of Diabetes Self-Management and Care · doi:10.1177/0145721714529608 · Cited by 39
Insulin for the treatment of hyperkalemia: a double-edged sword?
Li, T., & Vijayan, A. (2014) · Clinical Kidney Journal · doi:10.1093/ckj/sfu049 · Cited by 46
“9 mmol/ L] is recommended as the alert value even though symptoms of hypoglycemia usually develop at a level below this threshold [22, 23].”
BackgroundBronstone, A., & Graham, C. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816633233 · Cited by 38
“In adults, severe hypoglycemia is defined as hypoglycemia that requires assistance from another person to actively administer carbohydrates, glucagon, or take other corrective actions.(6) A review of the literature indicates that most studies of adults with T1DM have reported annual incidence rates of approximately 1…”
BackgroundAbdul-Ghani, M., Migahid, O., Megahed, A., Adams, J., Triplitt, C., DeFronzo, R. A., Zirie, M., & Jayyousi, A. (2017) · Diabetes Care · doi:10.2337/dc16-1738 · Cited by 39
“Insulin is very effective in lowering the plasma glucose concentration, but requires an injection and home glucose monitoring, causes hypoglycemia, and promotes weight gain (11).”
BackgroundInfluentialCardona, S., Gomez, P. C., Vellanki, P., Anzola, I., Ramos, C., Urrutia, M. A., Haw, J. S., Fayfman, M., Wang, H., Galindo, R. J., et al. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2018-000607 · Cited by 38
Sinclair, A. J., Dunning, T. L., Dhatariya, K., & an International Group of Experts (2019) · Diabetic Medicine · doi:10.1111/dme.14135 · Cited by 46
Lindner, N., Kuwabara, A., & Holt, T. (2021) · Systematic Reviews · doi:10.1186/s13643-021-01644-2 · Cited by 47
“Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society.”
BackgroundInfluentialParrinello, C. M., Rastegar, I., Godino, J., Miedema, M. D., Matsushita, K., & Selvin, E. (2015) · Diabetes Care · doi:10.2337/dc15-0016 · Cited by 38
Marker, A. M., Monzon, A. D., Nelson, E.-L., Clements, M. A., & Patton, S. R. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0244 · Cited by 37
Fritzen, T. M., Weinert, L. S., Denk, I. B., Deuschle, J. A. S., Conte, I. S., Menegolla, M. P., & Rodrigues, T. D. C. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000386 · Cited by 42
“Age of diagnosis, years 17 (12-25) 16 (11-26) 0.”
BackgroundInfluentialPeyser, T. A., Nakamura, K., Price, D., Bohnett, L. C., Hirsch, I. B., & Balo, A. (2015) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2014.0415 · Cited by 37
Endocrine Emergencies With Neurologic Manifestations
Ishii, M. (2017) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000467 · Cited by 50
Effects of perioperative tight glycemic control on postoperative outcomes: a meta-analysis
Kang, Z.-Q., Huo, J.-L., & Zhai, X. (2018) · Endocrine Connections · doi:10.1530/ec-18-0231 · Cited by 47
Ringholm, L., Roskjær, A. B., Engberg, S., Andersen, H. U., Secher, A. L., Damm, P., & Mathiesen, E. R. (2019) · Diabetologia · doi:10.1007/s00125-018-4794-9 · Cited by 40
Evaluating Glucose Control With a Novel Composite Continuous Glucose Monitoring Index
Leelarathna, L., Thabit, H., Wilinska, M. E., Bally, L., Mader, J. K., Pieber, T. R., Benesch, C., Arnolds, S., Johnson, T. K., Heinemann, L., et al. (2019) · Journal of Diabetes Science and Technology · doi:10.1177/1932296819838525 · Cited by 41
“Hypoglycemia is one of the most significant barriers to achieving near-normal glucose control for people living with diabetes and their caregivers.(14) One of the limitations of the original glucose pentagon may be the noninclusion of a measure of hypoglycemia.”
BackgroundBergenstal, R. M., Peyrot, M., Dreon, D. M., Aroda, V. R., Bailey, T. S., Brazg, R. L., Frias, J. P., Johnson, M. L., Klonoff, D. C., Kruger, D. F., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0298 · Cited by 37
“Severe hypoglycemia was defined as an event requiring the assistance of another person to actively administer carbohydrate (including intravenous dextrose), glucagon, or other resuscitative actions.(23) Nocturnal hypoglycemia was defined as any hypoglycemic event occurring between midnight and 6 A.”
BackgroundSelf-citationHalberg, I. B., Lyby, K., Wassermann, K., et al. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00772-2 · Cited by 37
Samya, V., Shriraam, V., Jasmine, A., Venguidesvarane, A. G., Rani, M. A., Durai, V., Gayathri, T., & Mahadevan, S. (2019) · Journal of Primary Care & Community Health · doi:10.1177/2150132719880638 · Cited by 46
“individuals with comorbidities and that it is essential to treat patients in such a way as to minimize the risk of developing hypoglycemia.(11) ADA and European Association for the Study of Diabetes (EASD) guidelines recommend hypoglycemia risk to be considered while treatingT2DM patients.”
BackgroundClinical results of islet transplantation
Maffi, P., & Secchi, A. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.04.010 · Cited by 36
Maiorino, M. I., Bellastella, G., Petrizzo, M., Improta, M. R., Brancario, C., Castaldo, F., Olita, L., Giugliano, D., & Esposito, K. (2013) · Endocrine · doi:10.1007/s12020-013-0060-6 · Cited by 42
Reliability of Trained Dogs to Alert to Hypoglycemia in Patients With Type 1 Diabetes
LOS, E. A., Ramsey, K., Guttmann‐Bauman, I., & Ahmann, A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816666537 · Cited by 47
QT prolongation caused by insulin-induced hypoglycaemia – An interventional study in 119 individuals
Kacheva, S., Karges, B., Göller, K., Marx, N., Mischke, K., & Karges, W. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.11.021 · Cited by 38
Challenges Imposed By Hypoglycemia in Adults With Type 1 Diabetes
Martyn-Nemeth, P. A., Duffecy, J. L., Fritschi, C., & Quinn, L. (2018) · Clinical Nursing Research · doi:10.1177/1054773818774702 · Cited by 49
Lucidi, P., Porcellati, F., Bolli, G. B., & Fanelli, C. G. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1065-6 · Cited by 38
Exercise in Pregnant Women with Diabetes
Peters, T. M., & Brazeau, A. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1204-8 · Cited by 40
Galindo, R. J., Parkin, C. G., Aleppo, G., Carlson, A. L., Kruger, D. F., Levy, C. J., Umpierrez, G. E., & McGill, J. B. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0107 · Cited by 39
Supporting parents of children with type 1 diabetes mellitus: a literature review
Zysberg, L., & Lang, T. (2015) · Patient Intelligence · doi:10.2147/pi.s77566 · Cited by 41
“SeS and ethnic background A literature review of English-language studies that were published between January 1985 and May 2009 suggests that children of ethnic minorities in the US bear a greater health burden and experience poorer outcomes than white chronically ill children.(23) Additional research strengthens this…”
Management of Hypoglycemia in Children and Adolescents with Type 1 Diabetes Mellitus
McGill, D. E., & Levitsky, L. L. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0771-1 · Cited by 39
Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Hypoglycemia
Ja’arah, D., Al Zoubi, M. S., Abdelhady, G., Rabi, F., & Tambuwala, M. M. (2021) · Clinical Medicine Insights: Endocrinology and Diabetes · doi:10.1177/11795514211051697 · Cited by 35
Degludec: the new ultra-long insulin analogue
Tambascia, M. A., & Eliaschewitz, F. G. (2015) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-015-0037-0 · Cited by 41
“IDeg is an ultra-long insulin analog that exhibits low intra-individual variability and whose efficacy is comparable to IGlar, but which presents as advantages flexibility in dose timing and lower risk of hypoglycemia, benefits that may impact quality of life and adherence to therapy [25].”
BackgroundShriraam, V., Mahadevan, S., Anitharani, M., Jagadeesh, N. S., Kurup, S., Vidya, T., & Seshadri, K. (2016) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.196002 · Cited by 41
Fear of hypoglycaemia in patients with type 1 and 2 diabetes: a systematic review
Zhang, Y., Li, S., Zou, Y., Wu, X., Bi, Y., Zhang, L., Yuanyuan, Gong, W., & Hayter, M. (2020) · Journal of Clinical Nursing · doi:10.1111/jocn.15538 · Cited by 43
Heller, S. R., Geybels, M. S., Iqbal, A., Liu, L., Wagner, L., & Chow, E. (2021) · Diabetologia · doi:10.1007/s00125-021-05556-7 · Cited by 37
“1 mmol/l (56 mg/dl), and severe hypoglycaemia defined as an episode requiring assistance of another person to actively administer carbohydrate or glucagon, or to take other corrective action [6].”
BackgroundSelf-citationHeller, S., Mathieu, C., Kapur, R., Wolden, M. L., & Zinman, B. (2016) · Diabetic Medicine · doi:10.1111/dme.13002 · Cited by 34
Self-citationDandona, P., & Chaudhuri, A. (2017) · International Journal of Clinical Practice · doi:10.1111/ijcp.12937 · Cited by 35
New uses and formulations of glucagon for hypoglycaemia
Beato-Víbora, P. I., & Arroyo-Díez, F. J. (2019) · Drugs in Context · doi:10.7573/dic.212599 · Cited by 40
Desjardins, K., Brazeau, A., Strychar, I. M., & RABASA-LHORET, R. P. R. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12232 · Cited by 37
“Moreover, in a recent report, the American Diabetes Association and the Endocrine Society evoked the absence of consensus on this practice [16].”
BackgroundCimmaruta, D., Maiorino, M., Scavone, C., Sportiello, L., Rossi, F., Giugliano, D., Esposito, K., & Capuano, A. (2016) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2016.1221402 · Cited by 33
“However, intensive insulin regimens are related to a higher risk of hypoglycemia and weight gain, both of them being related to worse long-term outcomes [9,10].”
BackgroundGarg, S. K., Wernicke‐Panten, K., Rojeski, M., Pierre, S., Kirchhein, Y., & Jedynasty, K. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2017.0117 · Cited by 34
Yang, L., Zhang, L., He, H., Zhang, M., & An, Z. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-0674-7 · Cited by 42
Espeland, M. A., Pratley, R. E., Rosenstock, J., Kadowaki, T., Seino, Y., Zinman, B., Marx, N., McGuire, D. K., Andersen, K. R., Mattheus, M., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14254 · Cited by 35
“Hypoglycaemia is also associated with adverse psychological outcomes and reduced quality of life, and fear of this side effect contributes to therapeutic inertia by physicians.(22,23,25) Interestingly, in addition to the lower risk of hypoglycaemia with linagliptin in older patients in CAROLINA, there were also signif…”
BackgroundOyagüez, I., Merino-Torres, J. F., Brito, M., Bellido, V., Cardona-Hernandez, R., Gomez-Peralta, F., & Morales-Perez, F. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001330 · Cited by 33
Palliative and end of life care of people with diabetes: issues, challenges and strategies
Dunning, T., & Martin, P. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.09.018 · Cited by 32
Maynard, G., Schnipper, J. L., Messler, J., Ramos, P., Kulasa, K. M., Nolan, A., & Rogers, K. M. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814532237 · Cited by 33
Relationships among different glycemic variability indices obtained by continuous glucose monitoring
Saisho, Y., Tanaka, C., Tanaka, K., Roberts, R., Abe, T., Tanaka, M., Meguro, S., Irie, J., Kawai, T., & Itoh, H. (2014) · Primary care diabetes · doi:10.1016/j.pcd.2014.10.001 · Cited by 34
“First, we used blood glucose <70 mg/dl as the definition of hypoglycemia [17], but the use of another threshold or definition of hypoglycemia might affect the results differently.”
BackgroundMethod(2017) · The American Pharmacists Association eBooks · doi:10.21019/9781582122885.nationalclinicalguidelines · Cited by 32
Hypoglycaemia and gastric emptying
Marathe, C. S., Marathe, J. A., Rayner, C. K., Kar, P., Jones, K. L., & Horowitz, M. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13570 · Cited by 32
Individualized Glycemic Goals and an Expanded Classification of Severe Hypoglycemia in Diabetes
Cryer, P. E. (2017) · Diabetes Care · doi:10.2337/dc16-1741 · Cited by 31
“Thus, it is proposed to expand the classification of severehypoglycemia in diabetes to include, in addition to a hypoglycemic event requiring the assistanceof another person (17), a history of a measured glucose concentration ,50 mg/dL (2.”
BackgroundInfluentialSelf-citationVolčanšek, Š., Lunder, M., & Janež, A. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0131 · Cited by 33
Nishioka, Y., Okada, S., Noda, T., Myojin, T., Kubo, S., Ohtera, S., Kato, G., Kuroda, T., Ishii, H., & Imamura, T. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13153 · Cited by 28
“Meglitinides 610,799 (8) 5,200 (11) 605,599 (8) 0.”
InfluentialAroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 31
Amod, A., Buse, J. B., McGuire, D. K., Pieber, T. R., Pop‐Busui, R., Pratley, R. E., Zinman, B., Hansen, M. B., Jia, T., Mark, T., et al. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00715-x · Cited by 34
Suteau, V., Saulnier, P., Wargny, M., Gonder-Frederick, L. A., Gand, E., Chaillous, L., Allix, I., Dubois, S. G., Bonnet, F., Leguerrier, A.-M., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107988 · Cited by 39
Kuniß, N., Rechtacek, T., Kloos, C., Müller, U. A., Roth, J., Burghardt, K., & Kramer, G. (2017) · Acta Diabetologica · doi:10.1007/s00592-017-0972-3 · Cited by 36
Seaquist, E. R., Blonde, L., McGill, J. B., Heller, S. R., Kendall, D. M., Bumpass, J. B., Pompilio, F. M., & Grant, M. L. (2020) · Diabetic Medicine · doi:10.1111/dme.14202 · Cited by 30
Self-citationPatton, S. R., Noser, A. E., Clements, M. A., Dolan, L. M., & Powers, S. W. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0389 · Cited by 31
Cavaiola, T. S., Kiriakov, Y., & Reid, T. (2019) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.11.015 · Cited by 33
“OTHER CONSIDERATIONS IN T2D TREATMENT CHOICE Minimizing hypoglycemia risk is a key principle of T2D management;(5) hypoglycemia intimidates patients and physicians, limits effective titration of basal insulin and treatment intensification, and, if unchecked, increases morbidity and mortality.(16,56,57) Although a 5-ye…”
BackgroundDanne, T., Pettus, J., Giaccari, A., Cariou, B., Rodbard, H. W., WEINZIMER, S. A., Bonnemaire, M., Sawhney, S., Stewart, J., Wang, S. Q., et al. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0157 · Cited by 35
Sepúlveda, E., Poínhos, R., Nata, G., Carvalho, D. M., Neves, J. S., Seixas, D., Choudhary, P., Vicente, S., & Amiel, S. A. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0034 · Cited by 32
Mathieu, C., Dandona, P., Birkenfeld, A. L., Hansen, T. K., Iqbal, N., Xu, J. L., Repetto, E., Scheerer, M. F., THOREN, F. A., & Phillip, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14144 · Cited by 31
Lingvay, I., Capehorn, M., Catarig, A., Johansen, P., Lawson, J., Sandberg, A., Shaw, R., & Paine, A. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa577 · Cited by 31
“*Defined as an episode of hypoglycemia that was severe according to the ADA classification (28) or confirmed by a glucose value <56 mg/dL, with symptoms consistent with hypoglycemia.”
BackgroundEffects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes
Reid, L. J., Baxter, F., & Forbes, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14570 · Cited by 34
Barrea, L., Vetrani, C., Caprio, M., Ghoch, M. E., Frías-Toral, E., Mehta, R. J., Méndez, V., Moriconi, E., Paschou, S. Α., Pazderska, A., et al. (2021) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1980766 · Cited by 34
Treatment of Hypoglycemia in Adult Patients with Type 1 Diabetes: An Observational Study
Savard, V., Gingras, V., Leroux, C., Bertrand, A., Desjardins, K., Mircescu, H., & RABASA-LHORET, R. P. R. (2016) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.05.008 · Cited by 44
Frequency and Predictors of Self-Reported Hypoglycemia in Insulin-Treated Diabetes
Malkani, S., & Kotwal, A. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7425925 · Cited by 32
Prevalence of hypoglycaemia in a random population after Roux-en-Y gastric bypass after a meal test
Emous, M., van den Broek, M., Wijma, R. B., de Heide, L. J. M., van Dijk, G., Laskewitz, A. J., Totté, E., Wolffenbuttel, B. H. R., & van Beek, A. P. (2019) · Endocrine Connections · doi:10.1530/ec-19-0268 · Cited by 31
Heller, S. R., Buse, J. B., Ratner, R. E., Seaquist, E. R., Bardtrum, L., Hansen, C. T., Tutkunkardas, D., & Moses, A. C. (2019) · Diabetes Care · doi:10.2337/dc18-2361 · Cited by 37
“0 mmol/L; and level 3, severe events requiring third-party intervention independent of a defined glucose value (9).”
BackgroundSelf-citationStress, hypoglycemia, and the autonomic nervous system
Haas, A., Borsook, D., Adler, G., & Freeman, R. (2022) · Autonomic Neuroscience · doi:10.1016/j.autneu.2022.102983 · Cited by 30
Muneer, M. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/5584_2020_534 · Cited by 28
Wysham, C., Hood, R. C., Warren, M. L., Wang, T., Morwick, T. M., & Jackson, J. A. (2016) · Endocrine Practice · doi:10.4158/ep15959.or · Cited by 29
Li, M., Huang, X., Ye, H., Chen, Y., Yu, J. H., Yang, J.-X., & Zhang, X. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/7121356 · Cited by 36
“9mmol/L and/or symptoms and/or signs attributable to hypoglycemia [23].”
BackgroundDuncan, E., Fitzpatrick, D., Ikegwuonu, T., Evans, J. M. M., & Maxwell, M. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-019522 · Cited by 32
“Severe hypoglycaemia is a serious condition where the individual needs third-party assistance to be treated.(4) The prevalence of patients with T1D reporting severe hypoglycaemia (20%–25%)(5) is more common in insulin-treated T2D (6%),(6) but the incidence of severe hypoglycaemia rises strengths and limitations of thi…”
Impaired Awareness of Hypoglycaemia in Insulin-treated Type 2 Diabetes Mellitus
Alkhatatbeh, M. J., Abdalqader, N. A., & Alqudah, M. A. Y. (2018) · Current Diabetes Reviews · doi:10.2174/1573399814666180806144937 · Cited by 31
Witte, H., Nakas, C. T., Bally, L., & Leichtle, A. B. (2022) · JMIR Formative Research · doi:10.2196/36176 · Cited by 34
“This includes an increased length of stay [5], diabetic ketoacidosis or hyperglycemic hyperosmolar state in the case of hyperglycemia [6], increased risk of infection [7,8], admission to intensive care units (ICUs) [9], and an overall increase in mortality [10-12].”
Berikov, V., Андреевна, К. О., Semenova, J. F., & Klimontov, V. V. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12081262 · Cited by 40
“Repeated episodes of hypoglycemia cause defective glucose counterregulation and contribute to the development of an impaired awareness of hypoglycemia [4].”
BackgroundZaharieva, D. P., Miadovnik, L. A., Rowan, C. P., Gumieniak, R. J., Jamnik, V., & Riddell, M. C. (2015) · Diabetic Medicine · doi:10.1111/dme.12857 · Cited by 32
Harris, S. B., Khunti, K., Landin‐Olsson, M., Galbo-Jørgensen, Bøgelund, Chubb, Gundgaard, & Evans, M. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s46805 · Cited by 31
“Non-severe events Have not experienced 1 (1) 3 (2) 14 (16) 49 (30) Less frequent than once every 3 months 5 (6) 13 (8) 12 (14) 24 (15) Once every 3 months 5 (6) 29 (18) 12 (14) 19 (12) Once a month 26 (31) 44 (27) 16 (19) 23 (14) Once a week 30 (35) 49 (30) 16 (19) 28 (17) Three times a week 18 (21) 24 (15) 15 (18) 19…”
Secher, A. L., Stage, E., Ringholm, L., Barfred, C., Damm, P., & Mathiesen, E. R. (2013) · Diabetic Medicine · doi:10.1111/dme.12383 · Cited by 34
Agesen, R. M., Kristensen, P. L., Beck‐Nielsen, H., Nørgaard, K., Perrild, H., Christiansen, J. S., Jensen, T., Hougaard, P., Parving, H. ‐., Thorsteinsson, B., et al. (2016) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.03.001 · Cited by 32
Metadata
- Authors
- Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R.
- Affiliations
- University of Minnesota (US)
- The Frist Clinic, Nashville, Tennessee;
- Mid-America Diabetes Associates, Wichita, Kansas; the
- Washington University in St. Louis (US)
- University of Tennessee Health Science Center (US)
- Park Nicollet Clinic (US)
- University of Sheffield (GB)
- University of South Florida (US)
- Boston University (US)
- Walter Reed National Military Medical Center (US)
- Corresponding author
- Seaquist, Elizabeth R.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-04-13
- Volume
- 36
- Issue
- 5
- Pages
- 1384-1395
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3631867
- OpenAlex
- W2109416725
- Cited by
- 1,389
- References
- 141
- Citations by year
- 2026: 43 · 2025: 47 · 2024: 62 · 2023: 66 · 2022: 92 · 2021: 127 · 2020: 119 · 2019: 149 · 2018: 148 · 2017: 151 · 2016: 129 · 2015: 129 · 2014: 92 · 2013: 33
- FWCI
- 100.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- American Diabetes Association
- Eli Lilly and Company
- Sanofi
- National Institute for Health and Care Research (NF-SI-0611-10248)
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Patient Safety and Medication Errors
- Keywords
- hypoglycemia, diabetes mellitus, hypoglycemia definition, hypoglycemia prevention, long-term outcomes, patient counseling, clinical guidelines
- MeSH terms
- Diabetes Mellitus, Humans, Hypoglycemia, Societies, Medical, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.